Abstract: The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods.
Type:
Application
Filed:
October 31, 2007
Publication date:
July 10, 2008
Applicant:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond
Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
August 20, 2007
Publication date:
July 3, 2008
Applicant:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
Abstract: The present invention describes antibodies that target IGF-1R, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification improves the sequence of said antibody and/or alters the effector function of said antibody. Also disclosed are methods of using the antibodies of the invention.
Type:
Application
Filed:
February 7, 2008
Publication date:
June 26, 2008
Applicant:
Xencor, Inc.
Inventors:
Aaron K. Chamberlain, Wei Dang, Gregory A. Lazar
Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
August 20, 2007
Publication date:
June 26, 2008
Applicant:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to novel, soluble, recombinant RANKL (Receptor Activator of Nuclear Factor—?B Ligand) variant proteins which may be expressed solubly in E. coli, variants that have substantially reduced binding to OPG, variants that act as RANKL antagonists, and methods for generating the same.
Type:
Grant
Filed:
July 1, 2003
Date of Patent:
June 3, 2008
Assignee:
Xencor, Inc.
Inventors:
John R. Desjarlais, Rene S. Hubert, Jamal El Yazal, Shannon A Marshall
Abstract: The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.
Type:
Application
Filed:
October 30, 2007
Publication date:
May 15, 2008
Applicant:
Xencor, Inc.
Inventors:
John R. Desjarlais, Jonathan Zalevsky, Gregory L. Moore
Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
August 20, 2007
Publication date:
March 6, 2008
Applicant:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
August 20, 2007
Publication date:
February 28, 2008
Applicant:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
Type:
Grant
Filed:
March 26, 2004
Date of Patent:
January 8, 2008
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen Kohl Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RI, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
June 21, 2007
Publication date:
December 13, 2007
Applicant:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
June 19, 2007
Publication date:
October 25, 2007
Applicant:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIa, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
June 21, 2007
Publication date:
October 25, 2007
Applicant:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIa, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
June 21, 2007
Publication date:
October 18, 2007
Applicant:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
June 19, 2007
Publication date:
October 11, 2007
Applicant:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to Fc variants having Increased affinity for Fc?RI, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
June 19, 2007
Publication date:
October 11, 2007
Applicant:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIIa, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
June 21, 2007
Publication date:
October 11, 2007
Applicant:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIIa, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
June 19, 2007
Publication date:
October 11, 2007
Applicant:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Application
Filed:
June 15, 2007
Publication date:
October 4, 2007
Applicant:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application.